Finally, manipulation of the miR-200–Zeb1 axis could also be relevant in noncancer settings: beta-cell dedifferentiation has been shown to be a hallmark beta-cell defect in type 2 diabetes; therefore, reversing this process could be a novel therapeutic strategy63–66. The gene discussed is ZEB1; the disease is type 2 diabetes mellitus.